Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Palvella Therapeutics Inc (PVLA)

Palvella Therapeutics Inc (PVLA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,152,590
  • Shares Outstanding, K 11,836
  • Annual Sales, $ 0 K
  • Annual Income, $ -17,430 K
  • EBIT $ -29 M
  • EBITDA $ -27 M
  • 60-Month Beta -0.16
  • Price/Sales -23,051.80
  • Price/Cash Flow N/A
  • Price/Book 28.89

Options Overview Details

View History
  • Implied Volatility 92.04% (-20.86%)
  • Historical Volatility 90.30%
  • IV Percentile 78%
  • IV Rank 30.43%
  • IV High 150.04% on 02/05/25
  • IV Low 66.67% on 12/18/25
  • Expected Move (DTE 7) 10.63 (11.50%)
  • Put/Call Vol Ratio 4.52
  • Today's Volume 232
  • Volume Avg (30-Day) 202
  • Put/Call OI Ratio 0.37
  • Today's Open Interest 4,842
  • Open Int (30-Day) 3,431
  • Expected Range 81.79 to 103.04

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.96
  • Number of Estimates 6
  • High Estimate -0.87
  • Low Estimate -1.03
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.10%

Price Performance

See More
Period Period Low Period High Performance
1-Month
82.38 +12.18%
on 01/05/26
114.69 -19.43%
on 12/22/25
-6.58 (-6.65%)
since 12/09/25
3-Month
65.93 +40.16%
on 10/10/25
114.69 -19.43%
on 12/22/25
+22.32 (+31.84%)
since 10/09/25
52-Week
12.02 +668.80%
on 01/14/25
114.69 -19.43%
on 12/22/25
+78.16 (+548.49%)
since 01/08/25

Most Recent Stories

More News
Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved Therapies

Phase 3 SELVA study evaluating QTORIN™ rapamycin 3.9% anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic malformations (microcystic LMs) remains on track, with topline results anticipated...

PVLA : 92.41 (-5.10%)
Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs

Seasoned dermatology and immunology executive brings more than 25 years of experience advancing and launching innovative therapies, including OPZELURA ® , povorcitinib, ILUMYA®, ODOMZO ® , REMICADE...

PVLA : 92.41 (-5.10%)
Palvella Therapeutics Granted FDA Fast Track Designation for QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Angiokeratomas

Fast Track designation designed to facilitate the development, and expedite the review, of drugs to treat serious conditions and fill an unmet need With Fast Track designation, QTORIN™ rapamycin...

PVLA : 92.41 (-5.10%)
Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, Rare Genetic Disease with No...

73% of trial participants (11/15 participants) improved on the Overall Cutaneous Venous Malformations Investigator Global Assessment (Overall cVM-IGA) at Week 12; 67% of trial participants (10/15 participants)...

PVLA : 92.41 (-5.10%)
The Short-Sellers May Be Right About This Red-Hot Pharma Stock

Palvella Therapeutics (PVLA) is a clinical-stage biopharma stock with no revenue or FDA pipeline. However, the stock has exceptional price momentum with shares up 508% over the past year. PVLA is trading...

PVLA : 92.41 (-5.10%)
Palvella Therapeutics: Q3 Earnings Snapshot

Palvella Therapeutics: Q3 Earnings Snapshot

PVLA : 92.41 (-5.10%)
Palvella Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Palvella’s recently expanded rare disease pipeline now comprises QTORIN™-derived product candidates advancing in four serious, rare skin diseases that currently have no FDA-approved therapies ...

PVLA : 92.41 (-5.10%)
Palvella Therapeutics to Present at the Stifel 2025 Healthcare Conference

WAYNE, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or “the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing...

PVLA : 92.41 (-5.10%)
Palvella Therapeutics Announces New QTORIN™ Product Candidate, QTORIN™ Pitavastatin, for the Treatment of Disseminated Superficial Actinic Porokeratosis (DSAP), a Rare, Chronic, and Pre-Cancerous Genetic Skin Disease with No FDA-Approved Therapies

DSAP is a premalignant, progressive disease characterized by numerous expanding lesions which significantly impact quality-of-life; no FDA-approved therapies exist for the estimated more than 50,000 diagnosed...

PVLA : 92.41 (-5.10%)
Palvella Therapeutics to Host Third Quarter 2025 Financial Results and Corporate Update Conference Call on November 11, 2025

WAYNE, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc.  (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies...

PVLA : 92.41 (-5.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.

See More

Key Turning Points

3rd Resistance Point 110.97
2nd Resistance Point 107.06
1st Resistance Point 99.73
Last Price 92.41
1st Support Level 88.49
2nd Support Level 84.58
3rd Support Level 77.25

See More

52-Week High 114.69
Last Price 92.41
Fibonacci 61.8% 75.47
Fibonacci 50% 63.36
Fibonacci 38.2% 51.24
52-Week Low 12.02

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar